Revvity Inc. stock slips after CFRA downgrade but stays near 52-week high

Published on 09/19/2026 at 17:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity Inc. stock eased after CFRA cut its rating to Hold on September 18, 2026, even as it raised the price target to USD 157. The shares closed at USD 143.60, just below a fresh 52-week high reached earlier in the week.

Labor mit Wissenschaftlerin an Sequenziergerät und Reagenzflaschen — Fotorealistisches Life-Sciences-Labor zeigt Revvity Inc. (ISIN US76155R1086) mit automatisiertem Sequenziergerät und Reagenzien, Illustration mit AI erstellt.

Revvity Inc. stock (ISIN US76155R1086) closed at USD 143.60 on the New York Stock Exchange on September 18, 2026, down about 2.1% from the prior close after a strong seven-day gain of 15.40% drew profit-taking and fresh analyst scrutiny.

CFRA cuts rating but lifts target

As MSN reported on September 18, 2026, CFRA lowered its rating on Revvity from Buy to Hold, arguing that near-term upside looks less attractive after the stock's rally of nearly 50% year to date, but at the same time raised its price target from USD 145 to USD 157 per share.

According to MSN, CFRA analyst Daniel Rich pointed to recent valuation expansion and said he will be watching Revvity's third-quarter 2026 results for signs that instrument backlog is converting into revenue and that software sales momentum could support stronger earnings guidance.

Stock near post-pandemic high after deal news

Before the downgrade-driven pullback, Revvity shares had set a new 52-week high earlier in the week after management presented at Baird's 2026 Global Healthcare Conference, with the stock trading near a post-pandemic high, according to MSN.

Revvity's strong share performance has been supported by deal activity: Fidelity reported on September 18, 2026, that the company agreed to acquire Human Cell Design to strengthen its life sciences portfolio, particularly in GLP-1 therapies for diabetes and obesity, helping the stock gain roughly 15% over the week.

Valuation and recent performance in focus

Recent trading has been volatile around the CFRA call: Simply Wall St noted on September 19, 2026, that Revvity's share price slipped 2.24% in the latest session to around USD 143.45, after a seven-day return of 15.40% and a 90-day gain of 43.45%.

The same analysis highlighted that a widely followed fair-value narrative pegs Revvity's intrinsic value at about USD 157.61 versus the recent close near USD 143.45, implying a valuation gap of around USD 14 per share that investors are now reassessing in light of CFRA's more cautious stance.Simply Wall St

Insider sale adds another data point

Alongside the rating change, investors also registered an insider sale: according to StockTitan, senior vice president Tajinder S. Vohra sold 7,330 Revvity shares on September 16, 2026, at an average price of USD 140.88 per share under a Rule 10b5-1 plan adopted on May 15, 2026.

After this planned transaction worth about USD 1,032,650, Vohra still directly holds 6,635 shares, a reduction of just over half of his previous position, which provides an additional, though not necessarily negative, signal that management is willing to crystallize gains after the stock's strong advance.Ground News

Closing price and investor takeaway

Revvity Inc. stock ended the September 18, 2026, session at USD 143.60 on the New York Stock Exchange, with after-hours trading edging the price to about USD 144.71, leaving the shares just below a recent 52-week high and roughly USD 13 to USD 14 below CFRA's new USD 157 price target.